DIN 02450283 — BLINCYTO 38.5 MCG
BLINCYTO is a powder for solution of Blinatumomab marketed by AMGEN CANADA INC. The full Blinatumomab monograph covers indications, dosing, interactions and counselling for every strength and manufacturer.
- DIN
- 02450283
- Brand name
- BLINCYTO
- Active ingredient
- Blinatumomab
- Strength
- 38.5 MCG
- Dosage form
- POWDER FOR SOLUTION
- Route
- INTRAVENOUS
- Manufacturer
- AMGEN CANADA INC
- Health Canada status
- MARKETED
- Drug class
- Bispecific CD19/CD3-directed T-cell engager (BiTE) antibody
Product data from the Health Canada Drug Product Database, synced . Verify the live status at Health Canada.